United Therapeutics Stock Price on November 17, 2024
| UTHR Stock | USD 370.49 7.64 2.02% |
Below is the normalized historical share price chart for United Therapeutics extending back to June 17, 1999. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of United Therapeutics stands at 370.49, as last reported on the 29th of November, with the highest price reaching 379.06 and the lowest price hitting 370.02 during the day.
If you're considering investing in United Stock, it is important to understand the factors that can impact its price. Currently, United Therapeutics is very steady. United Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0546, which indicates the firm had a 0.0546% return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for United Therapeutics, which you can use to evaluate the volatility of the company. Please validate United Therapeutics' Semi Deviation of 1.84, coefficient of variation of 1279.33, and Risk Adjusted Performance of 0.0655 to confirm if the risk estimate we provide is consistent with the expected return of 0.0925%.
At this time, United Therapeutics' Total Stockholder Equity is relatively stable compared to the past year. As of 11/29/2024, Common Stock Shares Outstanding is likely to grow to about 50.7 M, while Common Stock Total Equity is likely to drop slightly above 531.1 K. . At this time, United Therapeutics' Price Earnings Ratio is relatively stable compared to the past year. As of 11/29/2024, Price Earnings To Growth Ratio is likely to grow to 0.35, while Price To Sales Ratio is likely to drop 4.20. United Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 17th of June 1999 | 200 Day MA 304.9125 | 50 Day MA 366.889 | Beta 0.561 |
United |
Sharpe Ratio = 0.0546
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | UTHR | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.69 actual daily | 15 85% of assets are more volatile |
Expected Return
| 0.09 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 4 96% of assets perform better |
Based on monthly moving average United Therapeutics is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of United Therapeutics by adding it to a well-diversified portfolio.
Price Book 2.767 | Enterprise Value Ebitda 8.9771 | Price Sales 6.1249 | Shares Float 40.9 M | Wall Street Target Price 382.222 |
Related Headline
Apellis Pharmaceuticals Headline on 15th of November 2024
EcoR1 Capital, LLC Adjusts Stake in Centessa Pharmaceuticals... by gurufocus.com
Overview of Recent Transaction by EcoR1 Capital, LLC On September 30, 2024, EcoR1 Capital, LLC , a prominent investment f
United Therapeutics Valuation on November 17, 2024
It is possible to determine the worth of United Therapeutics on a given historical date. On November 17, 2024 United was worth 385.19 at the beginning of the trading date compared to the closed value of 363.25. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of United Therapeutics stock. Still, in general, we apply an absolute valuation method to find United Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of United Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against United Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 400.45 | 401.53 | 385.47 | 386.27 | 252,750 | |
11/15/2024 | 385.19 | 385.19 | 359.11 | 363.25 | 619,976 |
| 363.00 | 363.00 | 355.79 | 359.21 | 367,394 |
| Backtest United Therapeutics | | | United Therapeutics History | | | United Therapeutics Valuation | Previous | Next |
United Therapeutics Trading Date Momentum on November 17, 2024
| On November 18 2024 United Therapeutics was traded for 359.21 at the closing time. The top price for the day was 363.00 and the lowest listed price was 355.79 . The trading volume for the day was 367.4 K. The trading history from November 18, 2024 was a factor to the next trading day price decrease. The trading price change against the next closing price was 1.11% . The trading price change against the current closing price is 3.19% . |
United Therapeutics Fundamentals Correlations and Trends
By evaluating United Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among United Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. United financial account trend analysis is a perfect complement when working with valuation or volatility modules.About United Therapeutics Stock history
United Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for United is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in United Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing United Therapeutics stock prices may prove useful in developing a viable investing in United Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 49.7 M | 50.7 M | |
| Net Income Applicable To Common Shares | 836.4 M | 878.2 M |
United Therapeutics Quarterly Net Working Capital |
|
United Therapeutics Stock Technical Analysis
United Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
United Therapeutics Period Price Range
Low | November 29, 2024
| High |
0.00 | 0.00 |
United Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
United Therapeutics November 29, 2024 Market Strength
Market strength indicators help investors to evaluate how United Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading United Therapeutics shares will generate the highest return on investment. By undertsting and applying United Therapeutics stock market strength indicators, traders can identify United Therapeutics entry and exit signals to maximize returns
United Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for United Therapeutics' price direction in advance. Along with the technical and fundamental analysis of United Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of United to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0655 | |||
| Jensen Alpha | 0.0067 | |||
| Total Risk Alpha | (0.14) | |||
| Sortino Ratio | 0.0049 | |||
| Treynor Ratio | 0.1219 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.